Pfizer acquires Hospira (HSP) for $17B cash. The transaction will be immediately accretive, adding $0.10-0.12 per share to earnings the first year after closing. The deal is expected to close in the first half of 2015.
Meanwhile, "AstraZeneca down premarket after posting Q4 loss". I suspect Mr. Read (CEO at PFE) isn't particularly disappointed that these two bits of news have come on the same day. In fact, my guess is that he did everything in his power to get a decision on Ibrance in time to announce the HSP deal on the day of the AZN earnings report. Why? So that, when PFE acquires AZN in X years, AZN shareholders will recall what happened last time. Sound crazy? Read about Pfizer's very long history of acquiring most everything in sight, some deals closing years after initial talks: http://ift.tt/TrZtYl
Submitted February 05, 2015 at 10:25AM by dag_1996 http://ift.tt/1xqTlw9
No comments:
Post a Comment